Literature DB >> 2145134

Transient neuromuscular impairment resulting from prolonged inhalation of halothane and enflurane.

T Tanigaki1, T Kondo, Y Ohta, H Yamabayashi.   

Abstract

Inhalation anesthesia first with halothane followed by enflurane relieved a patient with status asthmaticus who was refractory to conventional therapy including mechanical ventilation. After 13 days of anesthesia while on mechanical ventilation and employing nondepolarizing muscle relaxants, significant neuromuscular impairment, manifested by tetraplegia and sensory disturbance, developed. Anesthesia was discontinued on day 14, and the patient was weaned from mechanical ventilation on day 16. Over the next two months, the neuromuscular impairment markedly improved. Halothane was associated with cardiac arrhythmias and hepatitis necessitating replacement by enflurane. Enflurane appeared to be as effective a treatment for refractory asthma as halothane. The most probable cause of the neuromuscular impairment in our patient was the long-term use of inhalation anesthetics or nondepolarizing muscle relaxants.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2145134     DOI: 10.1378/chest.98.4.1012

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Quadriparesia following permissive hypercapnia and inhalational anesthesia in a patient with severe status asthmaticus.

Authors:  H O Zender; P Eggimann; P Bulpa; J C Chevrolet; P Jolliet
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 2.  Toxicity of inhaled agents after prolonged administration.

Authors:  Panumart Manatpon; W Andrew Kofke
Journal:  J Clin Monit Comput       Date:  2017-11-02       Impact factor: 2.502

3.  Reversible sensorimotor impairment following prolonged ventilation with isoflurane and vecuronium for acute severe asthma.

Authors:  H du Peloux Menagé; S Duffy; D W Yates; J A Hughes
Journal:  Thorax       Date:  1992-12       Impact factor: 9.139

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.